Clinical trial
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed…
NCT00441337 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00441337 |
|---|---|
| Title | A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies |
| Official title | A Phase 1, Open Label, Dose-escalation, Safety and Pharmacokinetic Study of MDX-1106 in Patients With Selected or Relapsed Malignancies |
| Acronym | MDX1106-01 |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer, Prostate Cancer |
| Intervention type | Biological |
| Interventions | MDX-1106 |
| Enrollment | 39 |
| Start date | Aug 1, 2006 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Feb 28, 2007 |
| Last update posted | Feb 20, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: